Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

New Zealand patent reform proposals – patent term extensions unlikely? (The SPC Blog) (IPKat)

Great Indian paradox – India preparing to challenge EU regulations at WTO while also attempting to seal Indo-EU FTA (Spicy IP) (Michael Geist)

Risk of wrongful medicines seizures seen in EU-Central America trade deal (IP Watch)

Unbiased HIV patent pool: A free-market, middle-income countries open model (IP Watch)

World’s leading life science patent litigation law firms revealed (IAM)

British official to lead International Union for the Protection of New Varieties of Plants as civil society interest rises (IP Watch)

UN claims victory in biodiversity talks, but outcomes not certain (IP Watch)

Some alternative methods to fighting fake drugs (Afro-IP) (Afro-IP)

Canada: Living separate and apart is never easy: Obviousness and inventiveness in pharmaceutical litigation (IP Osgoode)

EU/Central America: Risk of wrongful medicines seizures seen in EU-Central America trade deal (IP Watch)

India: Great Indian paradox – India preparing to challenge EU regulations at WTO while also attempting to seal Indo-EU FTA (Spicy IP) (Michael Geist)

Kenya: Kenyan anti-counterfeit legislation debate (Afro-IP)

NZ: Patent reform proposals – patent term extensions unlikely? (The SPC Blog) (IPKat)

US: How much damage does a lost patent do on the company value? – Myriad stock prices: Association of Molecular Pathology v USPTO (Innovationpartners)

US: Federal judge in Myriad patent case says invalidation of gene patents does not violate TRIPS: Association of Molecular Pathology v USPTO (KEI)

US: ACLU gene patent decision from an investor’s perspective: A black eye for the US patent system: Association of Molecular Pathology v USPTO (Holman’s Biotech IP Blog)

US: Association of Molecular Pathology v USPTO: What the parties are saying about the decision (Patent Docs)

US: Association of Molecular Pathology v USPTO: What everyone else is saying (Patent Docs)

US: ’60 Minutes’ and ‘Newshour’ take different approaches to covering gene patenting story: Association of Molecular Pathology v USPTO (Patent Docs)

US: Burrill Report podcast: Implications of gene patent ruling: Association of Molecular Pathology v USPTO (Patent Docs)

US: ‘Takings’ by Congress and the Courts (Patent Docs)

US: From lab to commercialisation: NIH licenses offer another path (PatentlyBIOtech)

Angiomax (Bivalirudin) – US: Hatch-Waxman patent term extension deadlines: Business day or calendar day?: The Medicines Company v Kappos (Peter Zura’s 271 Patent Blog)

Cancidas (Caspofungin) – US: District Court New Jersey: Merck & Co files patent infringement complaint following Para IV challenge by Sandoz (Patent Docs)

Clarinex (Desloratadine) – US: Mass forfeiture of 180-day exclusivity! – FDA’s approval letter for Orchid’s ANDA for generic Clarinex sets new 180-day exclusivity forfeiture (FDA Law Blog)

Cozaar (Losartan) / Hyzaar (Hydrochlorothiazide, Losartan) – US: Rarely used exception to the first permitted commercial marketing/use PTE criterion (FDA Law Blog)

Cozaar (Losartan) / Hyzaar (Hydrochlorothiazide, Losartan) – US: Generic Cozaar/Hyzaar 180-day exclusivity – Teva wins, FDA too (despite itself) in the Columbia District Court (FDA Law Blog)

Eloxatin (Oxaliplatin) – US: Fresenius Kabi enters into licensing and settlement agreements with Sanofi-Aventis (SmartBrief)

Eloxatin (Oxaliplatin) – US: Teva settles generic Eloxatin litigation with Debiopharma and Sanofi-Aventis (SmartBrief)

Gemzar (Gemcitabine) – US: Teva provides update on Gemzar litigation (SmartBrief)

Ilex – US: TTAB says ILEX not deceptive or deceptively misdescriptive for medicated skin paste: In re Medcon Products, Inc (not precedential) (TTABlog)

OxyContin (Oxycodone) – Germany: Landgericht Düsseldorf grants preliminary injunction against Sandoz: Mundipharma GmbH v. Sandoz Pharmaceuticals GmbH et al (EPLAW)

Prilosec (Omeprazole) – US: AstraZeneca ordered to pay attorney’s fees for ‘baseless’ suit to protect Prilosec OTC: AstraZeneca AB et al. v. Dr. Reddy’s Laboratories, Ltd. et al (Docket Report)

Retin-A Micro (Tretinoin) – US: District Court E D Texas: Promote Innovation files false marking complaint against Ortho-McNeil based on marking of Retin-A Micro product (Patent Docs)

Seasonique (Levonorgestrel, Ethinyl estradiol) – US: Teva receives favourable court decision regarding Seasonique (SmartBrief) (The IP Factor)

T2007 (Diphenyl barbituric acid) – US: Taro receives patent for new drug T2007 (The IP Factor) (SmartBrief)

Trilipix (Choline fenofibrate) – US: District Court New Jersey: Abbott files patent infringement complaint following Para IV challenge by Lupin (Patent Docs)

Valcyte (Valganciclovir) – US: District Court Delaware: Roche Palo Alto files patent infringement complaint following Para IV challenge by Endo Pharmaceuticals (Patent Docs)

Viagra (Sildenafil) – US: District Court E D Virginia: Pfizer files patent infringement complaint against Teva following Para IV challenge (Patent Docs)